Amerikanische Gesellschaft für Hirudotherapie

A hedgehog homolog regulates gut formation in leech (Helobdella)

Developmental biology published in Development (2003)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenomik & ProteomikKang D et al. · Development (Cambridge, England), 2003

Abstract

Signaling by the hedgehog (hh)-class gene pathway is essential for embryogenesis in organisms ranging from Drosophila to human. We have isolated a hh homolog (Hro-hh) from a lophotrochozoan species, the glossiphoniid leech, Helobdella robusta, and examined its expression by reverse transcription polymerase chain reaction (RT-PCR) and whole-mount in situ hybridization. The peak of Hro-hh expression occurs during organogenesis (stages 10-11). No patterned expression was detected within the segmented portion of the germinal plate during the early stages of segmentation. In stage 10-11 embryos, Hro-hh is expressed in body wall, foregut, anterior and posterior midgut, reproductive organs and in a subset of ganglionic neurons. Evidence that Hro-hh regulates gut formation was obtained using the steroidal alkaloid cyclopamine, which specifically blocks HH signaling. Cyclopamine induced malformation of both foregut and anterior midgut in Helobdella embryos, and no morphologically recognizable gonads were seen. In contrast, no gross abnormalities were observed in the posterior midgut. Segmental ectoderm developed normally, as did body wall musculature and some other mesodermal derivatives, but the mesenchymal cells that normally come to fill most of the coelomic cavities failed to develop. Taken with data from Drosophila and vertebrates, our data suggest that the role of hh-class genes in gut formation and/or neural differentiation is ancestral to the bilaterians, whereas their role in segmentation evolved secondarily within the Ecdysozoa.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsDigestive SystemEmbryonic InductionHumansIn Situ HybridizationLeechesMolecular Sequence DataPhylogenySequence AlignmentSignal TransductionTissue Distribution

Zusammenfassung

Hro-hh, a hedgehog homolog in Helobdella robusta, regulates body-wall, foregut, anterior/posterior midgut, reproductive organs, and ganglionic neuron development. Cyclopamine inhibition disrupts foregut and anterior midgut formation.

Warum dies für die Hirudotherapie relevant ist

This study isolated and characterized a hedgehog (hh) homolog (Hro-hh) from the glossiphoniid leech Helobdella robusta, examining its expression during embryogenesis and its role in gut formation using cyclopamine to block HH signaling. The findings indicate that Hro-hh regulates foregut and anterior midgut development, with blocked signaling causing malformations in these structures as well as loss of gonads and coelomic mesenchymal cells. This work is purely developmental biology concerning a non-medicinal leech species and has no direct relevance to hirudotherapy, the leech secretome, or clinical ASH interests. It provides basic science insight into conserved signaling pathways across bilaterians but offers nothing applicable to therapeutic leech practice.

Zitation

A hedgehog homolog regulates gut formation in leech (Helobdella).

Kang D et al. · Development (Cambridge, England), 2003

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 26, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.